Mirum Q3 revenue $47.7M, LIVMARLI sales up 106%; CHENODAL/CHOLBAM acquisition completed

Mirum Pharmaceuticals, Inc.

2023-Q3 EPS reported -$3.28 revenue$116,820,000

Q3 2023 total revenue $47.7M (up 154% YoY); LIVMARLI global net sales $38.7M, +106% vs Q3 2022.
Acquisition of CHENODAL and CHOLBAM closed Aug 31; contributed $9M in Q3 sales.
Positive Phase 3 RESTORE for CHENODAL in CTX; NDA filing expected H1 2024; sNDA for LIVMARLI in PFIC PDUFA March 13, 2024.
Cash and investments $306M; convertible debt $316.3M; pipeline catalysts: EMBARK data by year-end, volixibat data H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Mirum Pharmaceuticals, Inc. reported third quarter 2023 results: revenue $47.7 million.

Period: third quarter 2023
Revenue: $47.7 million
Result: reported results

Exact text from the filing

EXHIBIT 99.1 Exhibit 99.1 Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update - Third quarter 2023 total revenue of $47.7 million - Completed acquisition of CHENODAL® and CHOLBAM® - Announced positive Phase 3 RESTORE study results evaluating CHENODAL (chenodiol) in patients with CTX; NDA filing expected in

View on SEC.gov

Browse all earnings releases →

Mirum Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001157523-23-001631

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.